Should Biotechnology Stock Neurosense Therapeutics Ltd (NRSN) Be in Your Portfolio Wednesday?

Neurosense Therapeutics Ltd (NRSN) is around the middle of the Biotechnology industry according to InvestorsObserver. NRSN received an overall rating of 53, which means that it scores higher than 53 percent of all stocks. Neurosense Therapeutics Ltd also achieved a score of 50 in the Biotechnology industry, putting it above 50 percent of Biotechnology stocks. Biotechnology is ranked 18 out of the 148 industries.

NRSN has an Overall Score of 53. Find out what this means to you and get the rest of the rankings on NRSN!

See Full NRSN Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 53 means the stock is more attractive than 53 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Neurosense Therapeutics Ltd Stock Today?

Neurosense Therapeutics Ltd (NRSN) stock has risen 2.61% while the S&P 500 has fallen -0.77% as of 11:40 AM on Wednesday, May 31. NRSN is up $0.04 from the previous closing price of $1.53 on volume of 6,957 shares. Over the past year the S&P 500 has risen 0.99% while NRSN is up 11.35%. NRSN lost -$1.07 per share the over the last 12 months. Click Here to get the full Stock Report for Neurosense Therapeutics Ltd stock.